Imux stock forecast 2025 relies heavily on gross margin

IMUX stock forecast 2025 relies heavily on gross margin expansion through licensing agreements, enhancing fiscal stability and investor confidence in sustained growth models. Immunic didn't record any revenue over the last year, indicating that it's an early stage company still developing its business. So while we can't look to sales to understand growth, we can look at how the cash burn is changing to understand how expenditure is trending over time. Over the last year its cash burn actually increased by 24%, which suggests that management are increasing investment in future growth, but not too quickly. That's not necessarily a bad thing, but investors should be mindful of the fact that will shorten the cash runway. While the past is always worth studying, it is the future that matters most of all. For that reason, it makes a lot of sense to take a look at our analyst forecasts for the company . Smart Portfolio is supported by our partner TipRanks. By connecting my portfolio to TipRanks Smart Portfolio I agree to their Terms of Use . IMUX stock forecast 2025 includes scenarios where strategic partnerships trigger milestone payments, directly impacting quarterly revenues and market capitalization before year-end revaluation cycles.